New pill BR101801 tested in patients with Hard-to-Treat blood cancers
NCT ID NCT04018248
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 31 times
Summary
This early-phase trial tested an experimental drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had come back or stopped responding to treatment. The study had two parts: first, finding a safe dose, and then checking how well that dose worked in a specific type of lymphoma. The main focus was on safety and side effects, not yet on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, South Korea
-
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Inje University Busan Paik Hospital
Busan, South Korea
-
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
-
Seoul national university hospital
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BR101801 (an experimental drug taken as capsules)
What this could lead to
If it works, this could point toward a new treatment option for people with certain advanced blood cancers that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 26 participants, so the main goal is safety and dosing, not yet proving effectiveness. Many early-stage drugs do not advance to later trials.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.